Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

In this study, we aimed to refine prognostication of older with acute myeloid leukemia (AML) after intensive chemotherapy. Five hundred and nine patients aged 60 years or older (median age, 68 years) were prospectively enrolled in the intensive Acute Leukemia French Association (ALFA)-1200 trial bet...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Gardin, Claude, Pautas, Cécile, Fournier, Elise, Itzykson, Raphaël, Lemasle, Emilie, Bourhis, Jean-Henri, Adès, Lionel, Marolleau, Jean-Pierre, Malfuson, Jean-Valère, Gastaud, Lauris, Raffoux, Emmanuel, Lambert, Juliette, Braun, Thorsten, Thomas, Xavier, Chantepie, Sylvain, Cluzeau, Thomas, de Botton, Stéphane, Berthon, Céline, Boissel, Nicolas, Duployez, Nicolas, Terré, Christine, Peffault de Latour, Régis, Michallet, Mauricette, Celli-Lebras, Karine, Preudhomme, Claude, Dombret, Hervé
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7218423/
https://ncbi.nlm.nih.gov/pubmed/32380535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001349
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados